226388-60-9

Upstream product

• 226396-67-4 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid (tetrahydro-pyran-2-yloxy)-amide 
• 226396-63-0 1-(tert-butyl) 4-ethyl 4-[(4-fluorophenyl)sulfonyl]piperidine-1,4-dicarboxylate 
• 226396-64-1 4-(4-fluorobenzenesulfonyl)-1-prop-2-ynylpiperidine-4-carboxylic acid ethyl ester 
• 226396-62-9 1-tert-butyl 4-ethyl 4-[(4-fluorophenyl)thio]piperidine-1,4-dicarboxylate 
• 226396-66-3 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid 
• 405-31-2 bis(4-fluorophenyl)disulfide 
• 226396-65-2 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid ethyl ester 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy

α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone h

Aromatic sulfone hydroxamic acids and their use as protease inhibitors

This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrec

Aromatic sulfone hydroxamic acid metalloprotease inhibitor

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,

Aromatic sulfone hydroxamic acids and their use as protease inhibitors

This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrec